Pre-eclampsia is a pregnancy-related syndrome characterized by hypertension and proteinuria that makes its appearance after 20 weeks of gestation. It develops approximately in 2–10% of all pregnancies. Pre-eclampsia, as a severe complication during pregnancy, is a major cause of maternal and perinatal morbidity and mortality.

The aim of the study was to assess the possibility of utilizing selected microRNAs at the earliest possible stage as safe biomarkers of severe complications of pregnancy, such as pre-eclampsia.

State of konowledge:
Nowadays, there are many trials aimed at finding effective methods for pre-eclampsia prediction at the early stage of pregnancy, before the onset of clinical signs. Although the precise pathophysiology of pre-eclampsia remains unknown, early prediction of the syndrome would allow the initiation of proper preventive therapy to savethe mother and future child. Current strategies for pre-eclampsia prediction are assessments of combinations of maternal risk factors, ultrasound parameters and different biomarkers (proteins, circulating cell free DNA and microRNAs). Studies of microRNAs in particular offer great potential for diagnosis and therapy in pregnancy-related disorders. The fraction of specific placenta-related circulating microRNAs in the serum of pregnant women who present symptoms of pre-eclampsia after 20 weeks of gestation, and show the strongest changes in the level, can play an important role in the development of placenta-related complications.

Further research into the level of microRNAs in the blood serum of pregnant women with pre-eclampsia will allow a practical way of utilizing selected microRNAs at the earliest possible stage as safe biomarkers of severe complications of pregnancy.

Kondracka A, Jaszczuk I, Koczkodaj D, Filip A, Kwaśniewska A. Blood serum microRNA profiles of pregnant women as biomarkers of preeclampsia evaluation. J Pre-Clin Clin Res. 2020; 14(4): 174–177. Doi:10.26444/jpccr/131597
Park H, Shim S, Cha D. Combined Screening for Early Detection of Pre-Eclampsia. Int J Mol Sci. 2015; 16(8): 17952–17974. doi: 10.3390/ijms160817952.
Hromadnikova I, Kotlabova K, Doucha J, et al. Absolute and related quantification of placenta – specific microRNAs in maternal circulation with placental insufficiency – related complications. JMD. March 2012; 14(2): 160 –167. doi: 10.1016/j.mold x.2011.11.0 03.
Hromadnikova I, Kotlabova K, Ondrackova M, et al. Circulating C19MC MicroRNAs in Pre-eclampsia, Gestational Hypertension, and Fetal Growth Restriction. Mediators of Inflammation. 2013. vol. 2013, article ID186041; 12 pages.
Hromadnikova I, Kotlabova K, Hympanova L, et al. First Trimester Screening of Circulating C19MC microRNAs Can Predict Subsequent Onset of Gestational Hypertension. PloS ONE 2014; 9(12): 113735. doi: 10.1371/journal.pone.0113735.
Hromadnikova I, Kotlabova K, Ondrackova M, et al. Expression Profile of C19MC microRNAs in Placental Tissue in Pregnancy-Related Complications. DNA AND CELL BIOLOGY, 2015; 34(6): 437–457. doi: 10.1089/dna.2014.2687.
Hromadnikova I, Kotlabova K, Ivankova K, et al. First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of pre-eclampsia and IUGR. PLoS ONE 2017; 12(2): 0171756. doi: 10.1371/journal.pone.0171756.
Zhao G, Zhou X, Chen S, et al. Differential expression of microRNAs in decidua – derived mesenchymal stem cells from patients with pre-eclampsia. Journal of Biomedical Science. 2014; 21: 81.
miRBase Release 22.1: (access: 2020.09.22).
miRTarBase Release 7: (access: 2020.09.22).
TargetScanHuman Release 7.1: (access: 2020.09.22).
Zhang Z, Yang T, Xiao J. Circular RNAs: Promising Biomarkers for Human Diseases. EBioMedicine. 2018.
Filip A, Grenda A, Popek S, et al. Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL – another piece in the puzzle. Ann Hematol. 2017 Jan; 96(1): 33–50. doi: 10.1007/s00277-016-2840-6. Epub 2016 Oct 12.
Chen X, Liang H, Zhang J, et al. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell. 2012; 3(1): 28–37. doi: 10.1007/s13238-012-2003-z.
Cretoiu D, Xu J, Xiao J, et al. Circulating microRNAs as potential molecular biomarkers in pathophysiological evolution of pregnancy. Disease Markers. Volume 2016, Article ID 3851054, 7 pages. http://d
Betoni JS, Derr K, Pahl MC, et al. MicroRNA analysis in placentas from patients with pre-eclampsia: comparison of new and published results. Hypertens Pregnancy. 2013; 32(4): 321–339. doi: 10.3109/10641955.2013.807819.
Cai M, Kolluru GK, Asif A. Small molecule, big prospects: microRNA in pregnancy and its complications. Journal of Pregnancy. 2017, Article ID 6972732, 15 pages. doi: 10.1155/2017/6972732.
Bounds KR, Chiasson VL, Pan LJ, et al. MicroRNAs: New Players in the Pathobiology of Preclampsia. Front Cardiovasc Med. 2017; 4: 60. doi: 10.3389/fcvm.2017.00060.
Pan M, Ge Q, Li H, et al. Sequencing the microRNAs in maternal plasma from women before and after parturition. J. Nanosci. Nanotechnol. 2012; 12(5): 4035–4043. doi: 10.1166/jnn.2012.6196.
Liu Z, Zhao X, Shan HY, et al. MicroRNA-520c-3p suppresses NLRP3 inflammasome activation and inflammatory cascade in pre-eclampsia by downregulating NLRP3. Inflammation Research.
Sandrim VC, Luizon MR, Palei AC, et al. Circulating microRNA expression profiles in pre-eclampsia: evidence of increased miR-885–5p levels. BJOG. 2016; 123: 2120–2128. doi: 10.1111/1471-0528.13903.